Date: 2016-09-01
Type of information: Nomination
Compound: chief business officer
Company: Advicenne (France)
Therapeutic area: Rare diseases - Genetic diseases
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On September 1st, 2016, Advicenne announced the nomination of Ludovic Robin as chief business & strategy officer. Ludovic Robin joins Advicenne to lead global commercial and corporate development focusing on the main business areas, both in the US and EU. He brings over 25 years’ experience in international R&D, marketing, sales and business development in the pharmaceutical industry. During his career, Ludovic launched more than 15 new original products for rare diseases or highly specialized indications. He started his career in the United Kingdom as scientist developing new cosmetology and dermatological formulations for Procter & Gamble and Stiefel laboratories. Then he came
back to France where he led various managerial and leadership roles in sales, marketing and business Development within L’Oréal, Servier and Laboratoires Expanscience. During this period, he originated, signed and executed 13 partnerships (registration, commercial) in more than 20 countries.
- In 2004, he joined Shire to launch the dermatology and the nephrology franchises. He served as marketing manager, Business unit Director, Marketing Director and Commercial
Operation Head for France and BeNeLux, in particular for nephrology and child psychiatry. He is a member of Shire French Executive board since 2008. Ludovic Robin received his Doctorate in Pharmacy (PharmD) and his Master in Industrial Pharmacy from Lyon University and completed his MBA at HEC Paris (and Mc GillMontreal).
Financial terms:
Latest news:
Is general: Yes
